REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN belongs to the group of anti-diabetic medicines used to treat type-2 diabetes mellitus. Type-2 diabetes mellitus is also known as non-insulin-dependent diabetes or adult-onset diabetes. It is a medical condition in which blood glucose levels are above normal due to insulin deficiency, insulin resistance, or both.
REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN is a combination of two drugs, namely: Remogliflozin etabonate and Vildagliptin. Remogliflozin etabonate helps in removing excess sugar from the body via urine. Vildagliptin works by decreasing the hormones that raise blood glucose levels and increasing insulin release from the pancreas. Together, REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN helps control blood sugar levels.
You are advised to take REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN for as long as your doctor has prescribed it for you, depending on your medical condition. In some cases, you may experience certain common side-effects such as stomach upset, diarrhoea, headache, nausea, and vomiting. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to consult your doctor if you experience these side effects persistently.
Consult your doctor before taking REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN if you are pregnant or breastfeeding. REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN is not recommended for children as safety and effectiveness have not been established. Avoid alcohol consumption while taking REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN as it might cause unpleasant side-effects. Inform your doctor about all the medicines you are taking and your health condition to rule out any unpleasant side effects/interactions.
Type-2 diabetes mellitus
REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN is a combination of two anti-diabetic drugs, namely: Remogliflozin etabonate and Vildagliptin. REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN is used to treat type-2 diabetes mellitus. Remogliflozin etabonate helps in removing excess sugar from the body via urine. Vildagliptin works by decreasing the hormones that raise blood glucose levels and increasing the release of insulin from the pancreas. Together, REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN helps control blood sugar levels.
Do not take REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN if you are allergic to any of its components. Inform your doctor if you have heart problems, diabetic ketoacidosis, skin disorder, acute pancreatitis, low blood sugar levels, kidney or liver problems. Consult your doctor if you are pregnant or breastfeeding. REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN is not recommended for children as safety and effectiveness have not been established. Avoid alcohol consumption while taking REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN as it might cause unpleasant side-effects. Inform your doctor about all the medicines you are taking and your health condition to rule out any unpleasant side effects.
Drug-Drug Interactions: REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN may interact with diuretics, corticosteroids, thyroid medicines.
Drug-Food Interactions: No interactions found/established.
Drug-Disease Interactions: Inform your doctor if you have diabetic ketoacidosis, dialysis, skin disorder, acute pancreatitis, low blood sugar levels, heart, kidney or liver problems.
You are recommended to avoid alcohol consumption while taking REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN to prevent unpleasant side effects.
Please consult your doctor if you have any concerns regarding this; your doctor will prescribe only if the benefits outweigh the risks.
Please consult your doctor if you have any concerns regarding this; your doctor will decide whether REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN can be taken by breastfeeding mothers or not.
It is not known if REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN affects your ability to drive. Drive or operate machinery only if you are alert.
Dose adjustment may be needed. REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN should be used with caution in patients with liver impairment/liver disease. Please consult your doctor if you have a liver impairment or any concerns regarding this.
Dose adjustment may be needed. REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN should be used with caution in patients with kidney impairment/kidney disease. Please consult your doctor if you have kidney impairment or any concerns regarding this.
REMOGLIFLOZIN ETABONATE+VILDAGLIPTIN is not recommended for children as safety and effectiveness have not been established.
Type-2 diabetes mellitus: It is also known as non-insulin-dependent diabetes. It is a chronic or lifelong disease that keeps the body from utilizing insulin properly. Diabetes is a medical condition in which blood glucose levels are above normal. People with type 2 diabetes either do not produce enough insulin, or the insulin produced cannot perform its function in the body (insulin resistance). Middle-aged or older individuals are most likely to suffer from type 2 diabetes; hence it is also known as adult-onset diabetes. Type 2 diabetes symptoms include lack of energy, tiredness, frequent urination, excess thirst, dry mouth, blurry vision, constant hunger, weight loss, and itchy skin.